Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neuroblastoma 2Neoplasms 2Neoplasm Metastasis 2Melanoma 2Glioblastoma 2Colorectal Neoplasms 2Brain Neoplasms 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor Cancer 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Mesothelial Neoplasm 1Neuroectodermal Tumors 1Nervous System Diseases 1Neoplasms, Neuroepithelial 1Neoplasms, Nerve Tissue 1Neoplasms, Glandular and Epithelial 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma, Malignant 1Lymphoma, Non-Hodgkin 1Liver Neoplasms 1Liver Diseases 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Kidney Neoplasms 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 24Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × Immunotherapy × Clear all
NCT02035358 2022-04-06

Immunotherapy Study for Metastatic Renal Cell Cancer

Lumos Pharma

Phase 1 Completed
18 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡